ACTRN12610000837022进行中（未招募）3 期
A Randomised Controlled Trial of the Efficacy and Safety of Alemtuzumab (MABCAMPATH) for Prevention of Graft Rejection and Preservation of Renal Function in Patients Receiving Kidney Transplants
ational University Hospital0 个研究点目标入组 63 人开始时间: 2010年10月6日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 63
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- •Aged 18 – 65 years
- •- Renal failure with no previous renal transplantation
- •- Cadaveric or live donor kidney transplant recipient
- •- Written informed consent given
排除标准
- •- Pregnant or nursing or woman of child bearing potential unwilling/unable to practice an acceptable form of birth control
- •- Major systemic or other illness that would, in the opinion of the investigator, interfere with the patient’s ability to comply with the protocol, compromise patient safety, or interfere with the interpretation of study results
- •- Multi-organ transplant recipient
- •- Prior renal transplants
- •- Previous treatment with alemtuzumab
- •- Patient requiring anti-lymphocyte preparations/interleukin receptor antibody preparations for induction therapy
- •- Patient requiring cyclosporine, mycophenolic acid analogues or Mammalian Target of Rapamycin (mTOR) inhibitors as initial therapy
- •- Use of other investigational agents within 6 weeks prior to transplantation
- •- Active systemic infection
- •- Human Immunodeficiency Virus (HIV), Hepatitis B surface antigen or anti-hepatitis C antibody positive (if Hepatitis C Virus Polymerase Chain Reaction (HCV PCR) unavailable) or Hepatitis C Virus Polymerase Chain Reaction (HCV PCR) positive
- •- Positive T lymphocyte cytotoxicity cross-match between recipient serum and donor cells
- •- Autoimmune hemolytic anemia
- •- Past history of anaphylaxis following exposure to humanised monoclonal antibodies
- •- Panel Reactive Antibodies (PRA) equal or greater than 50%
- •- Inability to undergo transplant biopsy, including patient who will require anticoagulation
- •- Cold ischemia time greater than 24 hours
- •- Patient whose graft function or perfusion cannot be demonstrated within 5 hours post-anastomosis.
研究者
相似试验
进行中（未招募）
1 期
Thyroid AntiBodies and LEvoThyroxine StudyThyroid autoimmunity and history of miscarriage or infertility.EUCTR2011-000719-19-GBniversity of Birmingham952
尚未招募
不适用
Postnatal Support App for First Time Mothers about Maternal Self-EfficacyAnxietyDepressionACTRN12618001580268Hunter Medical Research Institute174
已完成
不适用
A Randomised Controlled Trial of the Effectiveness of a Media-based Intervention on Intentions to Seek Help for Mental Health Difficulties among Australian MeACTRN12621001008819The University of Melbourne477
已完成
4 期
A Randomised Controlled Trial on the Effectiveness of Synbiotics on the Frequency and Duration of Loose Bowel Movement in Acute Adult Diarrheal Disease.loose bowel movement, acute adult diarrheaOral and Gastrointestinal - Normal oral and gastrointestinal development and functionACTRN12607000296437Francel Villarin38
招募中
1 期
A randomized controlled trial on the efficacy and safety of Gegen Qinlian decoction in the treatment of Damp-heat Type colorectal cancerColorectal CancerITMCTR2100004460Zhejiang Traditional Chinese Medicine Hospital